The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
暂无分享,去创建一个
R. Giugliano | E. Braunwald | C. Cannon | S. Murphy | E. Bohula | A. Eisen | Jeong-Gun Park | M. Blazing | Jennifer A. White
[1] R. Giugliano,et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.
[2] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[3] K. Sakamoto,et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. , 2015, Journal of the American College of Cardiology.
[4] G. Niccoli,et al. Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects? , 2015, Journal of the American College of Cardiology.
[5] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[6] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[7] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[8] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[9] C. Held,et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. , 2013, American heart journal.
[10] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[11] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[12] G. Stone,et al. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2012, JACC. Cardiovascular interventions.
[13] R. Califf,et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.
[14] R. Califf,et al. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). , 2008, The American journal of cardiology.
[15] Sanjiv J. Shah,et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. , 2008, Journal of the American College of Cardiology.
[16] J. Gore,et al. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. , 2007, International journal of cardiology.
[17] C. Held,et al. CLINICAL RESEARCH , 1996, Nursing Clinics of North America.
[18] C. Cannon,et al. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. , 2006, Critical pathways in cardiology.
[19] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.
[20] R. Califf,et al. Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial , 2002, Circulation.
[21] B. Gersh,et al. Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting. , 2000, The American journal of cardiology.
[22] B. Hoogwerf,et al. Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .
[23] B. Hoogwerf,et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. , 2000, Circulation.
[24] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[25] P. Stone,et al. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). , 1996, The American journal of cardiology.
[26] D. Waters,et al. Long-term prognosis after myocardial infarction in patients with previous coronary artery bypass surgery. , 1988, Journal of the American College of Cardiology.
[27] D. Waters,et al. Angiographic findings after myocardial infarction in patients with previous bypass surgery: explanations for smaller infarcts in this group compared with control patients. , 1985, Circulation.